316. Carnitine cycle disorder Clinical trials / Disease details


Clinical trials : 4 Drugs : 10 - (DrugBank : 4) / Drug target genes : 2 - Drug target pathways : 11

  
3 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02226419
(ClinicalTrials.gov)
August 20135/8/2013Fat and Sugar Metabolism During Exercise, With and Without L-carnitine in Patients With Carnitine Transporter DeficiencyFat and Carbohydrate Metabolism During Exercise, With and Without L-carnitine Supplementation in Patients With Carnitine Transporter DeficiencyCarnitine Transporter, Plasma-membrane, Deficiency ofDietary Supplement: Break in L-carnitine treatmentKaren Lindhardt MadsenRigshospitalet, DenmarkCompleted18 YearsN/ABoth14N/ANULL
2NCT00983788
(ClinicalTrials.gov)
October 200923/9/2009Effect of Bezafibrate on Muscle Metabolism in Patients With Fatty Acid Oxidation DefectsEvaluation of the Effect of Bezafibrate on Muscle Metabolism During Exercise in Patients With CPTII and VLCAD DeficiencyCarnitine Palmitoyltransferase II Deficiency;Very Long Chain Acyl Coa Dehydrogenase DeficiencyDrug: Bezafibrate;Other: PlaceboRigshospitalet, DenmarkInstitut de Myologie, Pitié-Salpêtrière Hospital, FranceCompleted18 Years70 YearsBoth12Phase 2Denmark
3NCT00336167
(ClinicalTrials.gov)
June 20069/6/2006Bezafibrate Trial in CPT2 DeficiencyClinical Trial on the Effect of Bezafibrate in the Muscular Form of Carnitine Palmitoyltransferase 2 DeficiencyCarnitine Palmitoyl Transferase 2 DeficiencyDrug: bezafibrate (drug)Assistance Publique - Hôpitaux de ParisAssociation Française contre les Myopathies (AFM), Paris;Institut National de la Santé Et de la Recherche Médicale, FranceRecruiting18 YearsN/ABoth12Phase 3France